NLRP3 and Parkinson disease: Our results revealed that NLRP3 also acts as an HSP90 client and further support the value of HSP90 inhibition in treating PD at the anti‐inflammatory level; they also highlight the importance of molecular chaperones in regulating Parkin function and PD pathogenesis.